Home › Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies
 

Keywords :   


Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies

2016-01-06 06:05:47| drugdiscoveryonline Home Page

Tetragenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, announced recently a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states –such as pain and autoimmune disorders

Tags: development program partnership discovery

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05Estée Lauder Companies Presents Research at the Society for Investigative Dermatology Annual ...
21.05Dove Launches Whole Body Deodorants for 72-Hour Odor Protection
21.05Drowsy Sleep Co Launches Eyelash Protecting Mask
21.05Growth Opportunities in Upcycled Ingredients Anticipated Through 2032
21.05Superior Environmental Solutions Acquires Arrowhead Environmental Services
21.05Kinderhook Partners with Apex Waste Solutions and Acquires Materials Management Company and All American Disposal
21.05Liebherr Appoints Hobgood as New GM of Corporate Responsibility and Sustainability
21.05Tennessee Recycling Center Closing Due to Continued Dumping of Un-Recyclable Materials
More »